Consequently, both systemic and tumor-associated CXCL8 is associated with resistance to or reduced clinical benefit of chemotherapy, radiotherapy, molecularly targeted therapy, or immune checkpoint inhibition therapy like blockade of PD-1 or PD-L1 [112, 113]. Here, CD274 is linked to neoplasm.